Harbour Investments’s Inovio Pharmaceuticals INO Stock Holding History

Harbour Investments’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261	Buy	237 +98	+71%	+$116	﹤0.01%	4504
2026 Q1	$242	Buy	139 +136	+4,533%	+$224	﹤0.01%	4414
2025 Q4	$5	Hold	3	–	–	﹤0.01%	3849
2025 Q3	$7	Buy	+3	New	+$6	﹤0.01%	3730
2023 Q4	–	Sell	-16	Closed	-$75	–	3157
2023 Q3	$75	Hold	16	–	–	﹤0.01%	2939
2023 Q2	$86	Hold	16	–	–	﹤0.01%	2958
2023 Q1	$157	Sell	16 -10	-38%	-$170	﹤0.01%	2892
2022 Q4	$482	Buy	26 +10	+63%	+$227	﹤0.01%	2798
2022 Q3	$0	Hold	16	–	–	﹤0.01%	2776
2022 Q2	$0	Buy	+16	New	+$451	﹤0.01%	2776
2021 Q4	$1K	Sell	16 -546	-97%	-$43.7K	﹤0.01%	2518
2021 Q3	$48K	Buy	562 +3	+0.5%	+$301	﹤0.01%	1792
2021 Q2	$62K	Sell	559 -5	-0.9%	-$480	﹤0.01%	1687
2021 Q1	$63K	Buy	+564	New	+$74.2K	﹤0.01%	1542

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Harbour Investments's INO Position: Q2 2026 in Review

Harbour Investments increased its Inovio Pharmaceuticals (INO) stake by 71% in Q2 2026, buying an estimated $116 and bringing the position to 237 shares worth $261. The position accounts for ﹤0.01% of the portfolio, ranked #4504.

Harbour Investments first reported a position in INO in Q1 2021 and has held it in 14 quarters since. The position peaked at $63K in Q1 2021. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Harbour Investments held 237 shares of Inovio Pharmaceuticals worth $261 as of Q2 2026.
Harbour Investments bought 98 Inovio Pharmaceuticals shares in Q2 2026, an estimated $116.
Inovio Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4504 holding.
Harbour Investments first reported a position in Inovio Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
Harbour Investments's Inovio Pharmaceuticals position peaked at $63K in Q1 2021.
102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.